SRPT Sarepta Therapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 5, 2026SRPT Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
SRPT Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
| Ex-date | Split | Type |
|---|---|---|
| July 12, 2012 | 1-for-6 | Reverse |
About Sarepta Therapeutics, Inc. - Common Stock Company overview from Wikipedia
Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs.
History
Sarepta started in Corvallis, Oregon on January 1, 1980 and was originally named Antivirals Inc. After occupying several research laboratory spaces in Corvallis, the company opened a production laboratory in Corvallis in February 2002 and was renamed AVI BioPharma Inc. The company made headlines in 2003 when it announced work on treatments for severe acute respiratory syndrome (SARS) and the West Nile virus. In July 2009, the company announced they would move their headquarters from Portland, Oregon, north to Bothell, Washington, near Seattle. At that time, the company led by president and CEO Leslie Hudson had 83 employees and quarterly revenues of $3.2 million. AVI had yet to turn a profit and had not yet developed any commercial products as of July 2009. The company lost $19.7 million in the second quarter of 2009, and then won an $11.5 million contract with the U.S. Department of Defense's Defense Threat Reduction Agency in October 2009. By this time, the company had completed its headquarters move to Bothell.
In 2012, the company moved a second time, to Cambridge, Massachusetts. At the time, CEO Chris Garabedian indicated the move was motivated by the need to recruit expertise in rare diseases. The Corvallis laboratory facility was closed in 2016.
In June 2017, Sarepta Therapeutics appointed former Allergan executive Doug Ingram as its new CEO to replace Edward Kaye who had announced plans to step down earlier that year.
In February 2019, Sarepta acquired five gene therapy candidates for $165 million after one of them, MYO-101, produced results with a new gene therapy candidate for patients with Limb-Girdle muscular dystrophy; two months after receiving a single treatment, muscles from all three patients were producing the protein they couldn't make on their own. In 2019, the FDA rejected a Serepta Duchenne muscular dystrophy drug before reversing course 3 months later.
The company opened a new Genetic Therapies Center of Excellence in Columbus, Ohio in October, 2021 in order to dramatically advance research into therapeutics for several muscular dystrophies that had begun at Nationwide Children's Hospital several years earlier. As of 2022, there are three FDA-approved DMD drugs in Sarepta Therapeutics' portfolio. In January 2023, Sarepta partnered with Catalent to manufacture delandistrogene moxeparvovec (SRP-9001).
In June 2023, the FDA approved Sarepta Therapeutics’ fourth therapy, delandistrogene moxeparvovec-rokl, the first gene therapy to treat Duchenne muscular dystrophy (DMD). The product was approved under the accelerated approval pathway for 4-5 year olds with a confirmed DMD diagnosis. Accelerated approval requires that the product be studied further to verify its clinical benefit.
In July 2025, Sarepta announced plans to lay off 500 employees, about 36% of its workforce, following the deaths of two patients linked to its Duchenne muscular dystrophy gene therapy, ELEVIDYS. The layoffs are part of a restructuring effort expected to generate around $400 million in cost savings by 2026.
Products
Its primary products are based on Morpholino oligomers (PMOs), synthetic nucleic acid analogs that were conceived of by James Summerton and invented by Summerton with Dwight Weller, originally developed under the name NeuGene Antisense. Since morpholino oligomers can form sequence-specific double-stranded complexes with RNA they are suitable use in antisense therapy. In one application, translation blocking, a morpholino oligomer binds to messenger RNA produced by a known disease-causing gene to prevent it from being translated into protein. Morpholinos can also work as splice-switching oligos, targeting pre-mRNA to alter splicing and so causing changes in the structure of the mature mRNA (the mechanism of the approved drug eteplirsen). Morpholinos have been tested for a wide range of applications including prevention of cardiac restenosis after angioplasty, treatment of coronary artery bypass grafts, treatment of polycystic kidney disease, redirection of drug metabolism, treatment of some mutations causing Duchenne muscular dystrophy (DMD), and inhibition of infectious diseases. Their greatest clinical and commercial success thus far has been in the treatment of DMD. A new class of Morpholino oligos, the peptide-linked Morpholinos or PPMO, are linked to an arginine-rich cell-penetrating peptide to enhance their delivery into cells and have entered clinical trials.
The Morpholino drug eteplirsen, targeting exon 51 of the dystrophin mRNA, was approved as a human therapeutic by the FDA in 2016 and antisense oligonucleotides for Morpholinos targeting other exons are also subsequently approved. Morpholinos have been used in preclinical studies to inhibit replication of a broad range of viruses, including influenza, West Nile virus, SARS, hepatitis C, dengue fever, Ebola and Calicivirus, all of which are single stranded RNA viruses. They are in advanced development for prevention and treatment of Ebola and Marburg viruses. In March 2013, the Company announced positive results from a non-human primate study of AVI-7288, the drug candidate for treatment of Marburg virus infection. The results showed that intramuscular administration of AVI-7288 resulted in survival rates up to 100 percent in monkeys exposed to this fatal virus. These results are similar to those in previous studies when the drug was given by intravenous injection.
In December 2019, golodirsen (Vyondys 53) received US FDA approval for the treatment of cases that can benefit from skipping exon 53 of the dystrophin transcript. The other approved PMO developed by Sarepta is casimersen (AMONDYS45) which is indicated for the treatment of DMD in patients amendable by exon 45 skipping.
In addition to development of Morpholinos as therapeutics, AVI has conducted six human trials for colorectal and pancreatic cancers using their cancer vaccine AVICINE.
In 2019, Sarepta signed a licensing agreement with Roche for the development, and commercialization outside of USA, for SRP-9001. In June 2023, ELEVIDYS (Delandistrogene moxeparvovec) was approved by the FDA for use in 4-5-year-old boys with mutations in the DMD gene. The FDA granted accelerated approval to ELEVIDYS, which requires that the product be further studied to verify its clinical benefit.
In June 2024, the U.S. Food and Drug Administration expanded approval of delandistrogene moxeparvovec to include individuals with Duchenne muscular dystrophy with a confirmed mutation in the DMD gene who are at least 4 years of age. The FDA granted traditional approval for ambulatory patients and accelerated approval for non-ambulatory patients.
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | SRPT | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | -10.95Y avg ≈-0.3 | ≈-0.3 | · | · | |
| P/S (TTM) | 0.95Y avg ≈7.6 | ≈7.6 | 31.2 | Undervalued | |
| P/B (MRQ) | 1.25Y avg ≈11.7 | ≈11.7 | 4.7 | Undervalued | |
| Price / FCF (TTM) | 22.65Y avg ≈-21.1 | ≈-21.1 | · | · | |
| Price / Cash Flow (TTM) | 16.75Y avg ≈-27.8 | ≈-27.8 | · | · | |
| Price / Tangible Book (MRQ) | 1.25Y avg ≈11.9 | ≈11.9 | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | SRPT | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Operating Margin (TTM) | -7.3%5Y avg ≈-33.0% | ≈-33.0% | -701.6% | Top tier | |
| EBITDA Margin (TTM) | -5.0%5Y avg ≈-29.5% | ≈-29.5% | -701.6% | Top tier | |
| Pretax Margin (TTM) | -6.6%5Y avg ≈-38.7% | ≈-38.7% | -713.3% | Top tier | |
| Net Profit Margin (TTM) | -6.9%5Y avg ≈-39.6% | ≈-39.6% | -660.8% | Top tier | |
| ROA (TTM) | -4.0%5Y avg ≈-13.2% | ≈-13.2% | -36.5% | Top tier | |
| ROE (TTM) | -9.5%5Y avg ≈-67.7% | ≈-67.7% | -59.5% | In line | |
| ROIC | -62.3%5Y avg ≈-53.9% | ≈-53.9% | -63.3% | Top tier |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | SRPT | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 4.45Y avg ≈4.1 | ≈4.1 | 7.2 | Low liquidity | |
| Quick Ratio (MRQ) | 2.35Y avg ≈3.1 | ≈3.1 | 4.9 | Low liquidity | |
| Interest Coverage | 18.35Y avg ≈-4.6 | ≈-4.6 | -76.8 | Strong liquidity |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | SRPT | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | 15.6%5Y avg ≈32.9% | ≈32.9% | · | · | |
| Revenue CAGR 3Y | 33.1%5Y avg ≈34.8% | ≈34.8% | · | · | |
| Revenue CAGR 5Y | 32.4% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | SRPT | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 0.65Y avg ≈0.4 | ≈0.4 | 0.1 | Top tier | |
| Inventory Turnover | 0.0 | · | · | · | |
| Receivables Turnover | 4.45Y avg ≈4.6 | ≈4.6 | 7.5 | Weak | |
| Revenue / Employee | ≈$2.6M | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 4, 2026 | $-0.05 | $0.26 | -119.0% |
| March 31, 2026 | $2.88 | $1.01 | 184.7% | |
| Dec. 31, 2025 | $-3.93 | $-1.26 | -213.0% | |
| Sept. 30, 2025 | $-0.01 | $-0.83 | 98.8% | |
| June 30, 2025 | $1.89 | $0.77 | 146.8% | |
| March 31, 2025 | $-4.60 | $-0.97 | -376.2% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.20B | $1.90B | $1.24B | $933M | $702M | $540M | $381M | $301M | $155M | $5M | $1M | $10M | |
| Cost of Revenue | $26M | · | · | · | · | · | · | · | · | $130.0K | · | · | |
| R&D Expense | · | · | · | · | · | · | · | $402M | $167M | $188M | $146M | $94M | |
| SG&A Expense | $492M | $558M | $482M | $451M | $283M | $318M | $285M | $208M | $123M | $84M | $75M | $49M | |
| Operating Expenses | $2.90B | $1.68B | $1.51B | $1.47B | $1.16B | $1.10B | $1.09B | $645M | $326M | $272M | $221M | $144M | |
| Operating Income | $-700M | $218M | $-268M | $-536M | $-460M | $-564M | $-706M | $-344M | $-172M | $-267M | $-220M | $-134M | |
| Interest Expense | $-38M | $-18M | $-22M | $-53M | $64M | $60M | $31M | $34M | $6M | $2M | $1M | · | |
| Interest Income | $31M | $31M | $36M | $16M | $354.0K | $3M | $7M | $7M | $2M | $507.0K | $890.0K | · | |
| Other Non-op | $-19M | $43M | $33M | $-28M | $-61M | $11M | $-236.0K | $-656.0K | $601.0K | $930.0K | $154.0K | $779.0K | |
| Pretax Income | $-702M | $261M | $-520M | $-690M | $-419M | $-553M | $-714M | $-363M | $-49M | $-267M | $-220M | · | |
| Income Tax | $11M | $26M | $16M | $14M | $-168.0K | $1M | $1M | $-692.0K | $2M | · | · | · | |
| Net Income | $-713M | $235M | $-536M | $-703M | $-419M | $-554M | $-715M | $-362M | $-51M | $-267M | $-220M | $-136M | |
| EPS (Basic) | $-7.13 | $2.47 | $-5.80 | $-8.03 | $-5.15 | $-7.11 | · | · | · | · | · | · | |
| EPS (Diluted) | $-7.13 | $2.34 | $-5.80 | $-8.03 | $-5.15 | $-7.11 | · | · | · | · | · | · | |
| Shares (Basic) | 100,120,000 | 95,075,000 | 92,398,000 | 87,559,000 | 81,262,000 | 77,956,000 | 73,615,000 | 66,250,000 | 58,818,000 | 48,697,000 | 42,290,000 | 40,026,000 | |
| Shares (Diluted) | 100,120,000 | 107,875,000 | 92,398,000 | 87,559,000 | 81,262,000 | 77,956,000 | 73,615,000 | 66,250,000 | 58,818,000 | · | · | · | |
| EBITDA | $-655M | $256M | $-223M | $-494M | $-422M | $-537M | $-675M | $-331M | $-164M | $-261M | · | $-130M |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $801M | $1.10B | $428M | $967M | $2.12B | $1.50B | $835M | $371M | $600M | $122M | $80M | $74M | |
| Short-term Investments | $138M | $252M | $1.25B | $1.02B | $0 | $436M | $290M | $803M | $479M | $195M | $112M | $137M | |
| Receivables | $398M | $602M | $400M | $215M | $153M | $101M | $91M | $49M | $29M | $5M | $4M | $2M | |
| Inventory | $915M | $750M | $323M | $204M | $186M | $232M | $171M | $125M | $84M | $13M | · | · | |
| Prepaid Expense | · | · | · | · | · | · | · | · | · | $1M | $3M | $3M | |
| Other Current Assets | $172M | $90M | $78M | $150M | $149M | $213M | $82M | $78M | $37M | $27M | $17M | $35M | |
| Current Assets | $2.54B | $3.07B | $2.58B | $2.56B | $2.60B | $2.49B | $1.47B | $1.43B | $1.23B | $373M | $225M | $248M | |
| PP&E (Net) | $345M | $340M | $227M | $180M | $191M | $190M | $130M | $97M | $43M | $38M | $37M | $39M | |
| PP&E (Gross) | $626M | $574M | $418M | $329M | $304M | $266M | $181M | $125M | $61M | $68M | $62M | $58M | |
| Accum. Depreciation | $280M | $234M | $191M | $149M | $113M | $76M | $51M | $28M | $18M | $30M | $25M | $20M | |
| Intangibles | $29M | $27M | $30M | $8M | $14M | $14M | $12M | $12M | $14M | $8M | $7M | $6M | |
| Other Non-current Assets | $156M | $80M | $137M | $163M | $293M | $204M | $174M | $107M | $22M | $4M | $4M | $2M | |
| Total Assets | $3.35B | $3.96B | $3.26B | $3.13B | $3.15B | $2.98B | $1.82B | $1.64B | $1.31B | $424M | $274M | $295M | |
| Accounts Payable | $281M | $214M | $165M | $96M | $77M | $111M | $68M | $34M | $8M | $30M | $20M | $12M | |
| Accrued Liabilities | $360M | $374M | $315M | $419M | $272M | $194M | $186M | $134M | $69M | $31M | $29M | $17M | |
| Short-term Debt | · | · | · | · | · | · | · | · | · | · | $2M | $2M | |
| Current Liabilities | $1.10B | $732M | $654M | $620M | $453M | $416M | $265M | $174M | $88M | $75M | $62M | $37M | |
| Capital Leases | $199M | $192M | $141M | $58M | $42M | $80M | $48M | · | · | · | · | · | |
| Other Non-current Liabilities | $2M | $2M | $3M | $42.0K | $11M | $20M | $5M | $16M | $6M | $6M | $6M | $7M | |
| Total Liabilities | $2.21B | $2.44B | $2.41B | $2.74B | $2.22B | $2.22B | $1.00B | $610M | $519M | $87M | $83M | $47M | |
| Long-term Debt | $829M | $1.14B | $1.24B | $1.54B | $564M | · | · | $421M | $431M | $18M | $27M | $7M | |
| Total Debt | · | $0 | $105M | · | · | · | · | · | · | · | · | $4M | |
| Common Stock | $11.0K | $10.0K | $9.0K | $9.0K | $9.0K | $8.0K | $8.0K | $7.0K | $6.0K | $5.0K | $5.0K | $4.0K | |
| Paid-in Capital | · | · | · | · | · | · | · | · | · | · | · | $927M | |
| Retained Earnings | $-4.88B | $-4.21B | $-4.45B | $-3.91B | $-3.21B | $-2.85B | $-2.29B | $-1.58B | $-1.22B | $-1.17B | $-899M | $-679M | |
| Treasury Stock | $25M | $0 | · | · | · | · | · | · | · | · | · | · | |
| AOCI | $272.0K | $-218.0K | $918.0K | $-2M | $-20.0K | $3.0K | $50.0K | $-99.0K | $-379.0K | $-120.0K | $-111.0K | $-95.0K | |
| Stockholders' Equity | $1.14B | $1.53B | $859M | $385M | $928M | $762M | $818M | $1.03B | $789M | $337M | $190M | $248M | |
| Liabilities + Equity | $3.35B | $3.96B | $3.26B | $3.13B | $3.15B | $2.98B | $1.82B | $1.64B | $1.31B | $424M | $274M | $295M | |
| Shares Outstanding | 104,964,220 | 96,900,496 | 93,731,831 | 87,950,117 | 87,126,974 | 79,374,247 | 75,184,863 | 71,071,887 | 64,791,670 | 54,759,234 | 45,629,529 | 41,311,512 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $45M | $38M | $44M | $42M | $38M | $27M | $24M | $12M | $8M | $6M | $5M | $4M | |
| Stock-based Comp | $123M | $184M | $183M | $233M | $114M | $108M | $79M | $50M | $30M | $30M | $32M | $20M | |
| Deferred Tax | $-363.0K | $-249.0K | $-165.0K | $-612.0K | $-309.0K | $-245.0K | $-376.0K | $-240.0K | · | · | · | · | |
| Amort. of Intangibles | $3M | $2M | $2M | $714.0K | $706.0K | $662.0K | $849.0K | $865.0K | $1M | $29.0K | · | · | |
| Restructuring | $42M | $0 | $0 | · | · | · | · | · | $3M | $4M | · | $14.0K | |
| Other Non-cash | $340M | $-663M | $-192M | $104M | $-176M | $527M | $150M | $-89M | $-220M | $-14M | · | $-17M | |
| Operating Cash Flow | $-205M | $-206M | $-501M | $-325M | $-443M | $107M | $-456M | $-389M | $-232M | $-246M | $-149M | $-129M | |
| CapEx | $102M | $137M | $76M | $31M | $38M | $82M | $60M | $61M | $12M | $5M | $3M | $25M | |
| Investing Cash Flow | $70M | $756M | $-166M | $-1.05B | $495M | $-122M | $287M | $-370M | $-179M | $-90M | · | · | |
| Debt Issued | · | · | · | $0 | $0 | $291M | $246M | · | $30M | · | $20M | · | |
| Net Debt Issued | · | · | · | $0 | · | $291M | · | · | $30M | · | · | $-94.0K | |
| Stock Issued | $20M | $0 | $0 | $0 | $0 | $312M | · | $513M | $354M | $365M | $120M | $95M | |
| Stock Repurchased | $25M | $0 | $0 | · | · | · | · | · | · | · | · | · | |
| Net Stock Activity | $-5M | · | · | $0 | · | $312M | $365M | $513M | $354M | $365M | · | · | |
| Financing Cash Flow | $-168M | $125M | $125M | $233M | $562M | $682M | $643M | $530M | $888M | $378M | · | · | |
| Net Change in Cash | $-304M | $675M | $-542M | $-1.14B | $614M | $668M | $473M | $-229M | $477M | $42M | $7M | $-183M | |
| Taxes Paid | $38M | $23M | $15M | $2M | $583.0K | $3M | $933.0K | $2M | $5M | · | · | · | |
| Free Cash Flow | $-307M | $-343M | $-577M | $-356M | $-482M | $25M | $-516M | $-450M | $-244M | $-251M | · | $-154M | |
| Levered FCF | $-269M | $-326M | $-600M | $-410M | $-545M | $-35M | $-547M | $-483M | $-250M | · | · | · |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -31.8% | 11.5% | -21.5% | -57.5% | -65.5% | -104.5% | -185.3% | -114.1% | -111.0% | -4920.3% | · | · | |
| Net Margin | -32.5% | 12.4% | -43.1% | -75.4% | -59.7% | -102.6% | -187.8% | -120.2% | -32.8% | -4930.2% | · | · | |
| Pretax Margin | -31.9% | 13.7% | -41.8% | -74.0% | -59.7% | -102.4% | -187.5% | -120.4% | -31.5% | · | · | · | |
| EBITDA Margin | -29.8% | 13.5% | -18.0% | -53.0% | -60.1% | -99.5% | -177.2% | -110.1% | -105.8% | -4816.8% | · | · | |
| ROA | -19.5% | 6.5% | -16.8% | -22.4% | -13.7% | -23.1% | -41.3% | -24.5% | -5.9% | -76.6% | · | -46.3% | |
| ROE | -57.1% | 17.1% | -66.0% | -172.5% | -59.9% | -67.0% | -78.9% | -43.3% | -9.0% | -101.4% | · | -54.9% | |
| ROIC | -62.3% | 12.9% | -28.6% | -142.0% | -49.5% | -74.2% | -86.4% | -33.2% | -22.7% | · | · | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.3 | 4.2 | 3.9 | 4.1 | 5.8 | 6.0 | 5.5 | 8.2 | 13.9 | 5.0 | · | 6.7 | |
| Quick Ratio | 1.2 | 2.7 | 3.2 | 3.6 | 5.0 | 4.9 | 4.6 | 7.0 | 12.5 | 4.3 | · | 5.8 | |
| Debt / Equity | · | 0.0 | 0.1 | · | · | · | · | · | · | · | · | 0.0 | |
| LT Debt / Equity | · | · | · | · | · | · | · | · | · | · | · | 0.0 | |
| Interest Coverage | 18.3 | -11.9 | -12.2 | -10.1 | -7.2 | -9.4 | -23.0 | -10.2 | -29.7 | · | · | · |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.6 | 0.5 | 0.4 | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.0 | · | · | |
| Inventory Turnover | 0.0 | · | · | · | · | · | · | · | · | 0.0 | · | · | |
| Receivables Turnover | 4.4 | 3.8 | 4.0 | 5.1 | 5.5 | 5.6 | 5.4 | 7.7 | 8.9 | 1.2 | · | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $10.87 | $15.77 | $9.17 | $4.38 | $10.65 | $9.60 | $10.88 | $14.52 | $12.18 | $6.15 | · | $5.99 | |
| Revenue / Share | $21.96 | $17.63 | $13.46 | $10.66 | $8.64 | $6.93 | $5.17 | · | · | · | · | · | |
| Cash Flow / Share | $-2.05 | $-1.91 | $-5.42 | $-3.72 | $-5.45 | $1.38 | $-6.20 | · | · | · | · | · | |
| Cash / Share | $7.63 | $11.38 | $4.57 | $10.99 | $24.28 | $18.93 | $11.11 | $5.22 | $9.26 | $2.24 | · | $1.78 | |
| EPS (TTM) | $-7.13 | $2.34 | $-5.80 | $-8.03 | $-5.15 | $-7.11 | $-3.37 | $-3.37 | $-0.80 | · | $-6.37 | $-6.37 |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 15.6% | 53.0% | 33.3% | 32.9% | 30.0% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 33.1% | 39.4% | 32.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 32.4% | · | · | · | · | · | · | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $2.20B | $1.90B | $1.24B | $933M | $702M | $540M | $381M | $301M | $155M | $5M | $1M | $10M | |
| Net Income TTM | $-713M | $235M | $-536M | $-703M | $-419M | $-554M | $-715M | $-362M | $-51M | $-267M | $-220M | $-136M | |
| Market Cap | $2.26B | $11.78B | $9.04B | $11.40B | $7.85B | $13.53B | $9.70B | $7.76B | $3.61B | $1.50B | · | $598M | |
| Enterprise Value | · | $10.43B | $7.47B | · | · | · | · | · | · | · | · | $391M | |
| P/E | -3.0 | 52.0 | -16.6 | -16.1 | -17.5 | -24.0 | -38.3 | -32.4 | -69.5 | · | -6.1 | -2.3 | |
| P/S | 1.0 | 6.2 | 7.3 | 12.2 | 11.2 | 25.1 | 25.5 | 25.8 | 23.3 | 277.1 | · | 61.3 | |
| P/B | 2.0 | 7.7 | 10.5 | 29.6 | 8.5 | 17.8 | 11.9 | 7.5 | 4.6 | 4.5 | · | 2.4 | |
| P / Tangible Book | 2.0 | 7.9 | 10.9 | 30.2 | 8.6 | 18.1 | · | · | · | · | · | · | |
| P / Cash Flow | -11.0 | -57.3 | -18.0 | -35.0 | -17.7 | 125.9 | -21.3 | -20.0 | -15.5 | -6.1 | · | -4.7 | |
| P / FCF | -7.3 | -34.4 | -15.7 | -32.0 | -16.3 | 535.6 | -18.8 | -17.2 | -14.8 | -6.0 | · | -3.9 | |
| EV / EBITDA | · | 40.8 | -33.4 | · | · | · | · | · | · | · | · | -3.0 | |
| EV / FCF | · | -30.4 | -12.9 | · | · | · | · | · | · | · | · | -2.5 | |
| EV / Revenue | · | 5.5 | 6.0 | · | · | · | · | · | · | · | · | 40.1 | |
| Earnings Yield | -33.1% | 1.9% | -6.0% | -6.2% | -5.7% | -4.2% | -2.6% | -3.1% | -1.4% | · | -16.5% | -44.0% |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $401M | $731M | $443M | $399M | $611M | $745M | $658M | $467M | $363M | $413M | $397M | $332M | $261M | $254M | $258M | $230M | |
| Gross Profit | · | · | $-29M | $219M | $361M | $474M | $506M | $338M | $316M | $309M | · | · | · | · | · | · | |
| SG&A Expense | $108M | $109M | $128M | $92M | $138M | $134M | $164M | $128M | $139M | $127M | $132M | $121M | $119M | $111M | $120M | $105M | |
| Operating Expenses | $388M | $372M | $855M | $503M | $496M | $1.05B | $497M | $445M | $364M | $379M | $372M | $353M | $395M | $392M | $365M | $362M | |
| Operating Income | $13M | $358M | $-412M | $-103M | $116M | $-300M | $162M | $22M | $-701.0K | $35M | $25M | $-21M | $-134M | $-138M | $-107M | $-131M | |
| Interest Expense | $-22M | $-22M | $-46M | $2M | $-5M | $-5M | $-24M | $5M | $5M | $-4M | $-39M | $5M | $5M | $6M | $-100M | $15M | |
| Interest Income | $6M | $6M | $8M | $7M | $5M | $10M | $8M | $8M | $8M | $7M | $9M | $10M | $8M | $9M | $9M | $5M | |
| Other Non-op | $-15M | $-15M | $-22M | $48M | $38M | $-83M | $10M | $12M | $14M | $7M | $16M | $-12M | $17M | $13M | $6M | $378.0K | |
| Pretax Income | $-2M | $343M | $-278M | $-194M | $154M | $-384M | $172M | $34M | $14M | $41M | $40M | $-33M | $-15M | $-513M | $-101M | $-256M | |
| Income Tax | $3M | $12M | $5M | $-14M | $-43M | $64M | $13M | $395.0K | $7M | $5M | $-5M | $8M | $9M | $4M | $8M | $1M | |
| Net Income | $-5M | $331M | $-412M | $-51M | $197M | $-448M | $159M | $34M | $6M | $36M | $46M | $-41M | $-24M | $-517M | $-109M | $-258M | |
| EPS (Basic) | $-0.05 | $3.15 | $-3.93 | $-0.50 | $2.01 | $-4.60 | $1.65 | $0.35 | $0.07 | $0.38 | $0.79 | $-0.46 | $-0.27 | $-5.86 | $-1.24 | $-2.94 | |
| EPS (Diluted) | $-0.05 | $2.88 | $-3.93 | $-0.50 | $1.89 | $-4.60 | $1.50 | $0.34 | $0.07 | $0.37 | $0.79 | $-0.46 | $-0.27 | $-5.86 | $-1.24 | $-2.94 | |
| Shares (Basic) | 105,431,000 | 104,988,000 | · | 100,237,000 | 98,005,000 | 97,362,000 | · | 95,390,000 | 94,618,000 | 93,991,000 | · | 88,889,000 | 88,743,000 | 88,186,000 | · | 87,628,000 | |
| Shares (Diluted) | 105,431,000 | 121,916,000 | · | 100,237,000 | 106,623,000 | 97,362,000 | · | 100,448,000 | 99,144,000 | 99,114,000 | · | 88,889,000 | 88,743,000 | 88,186,000 | · | 87,628,000 | |
| EBITDA | $13M | $369M | · | $-103M | $116M | $-290M | · | $22M | $-701.0K | $44M | · | $-21M | $-134M | $-127M | · | $-131M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $571M | $464M | $801M | $613M | $511M | $241M | $1.10B | $198M | $384M | $427M | $428M | $542M | $852M | $872M | $967M | $1.04B | |
| Short-term Investments | $217M | $189M | $138M | $238M | $290M | $282M | $252M | $1.00B | $1.08B | $963M | · | $1.19B | $1.01B | $1.01B | · | $1.03B | |
| Receivables | $377M | $395M | $398M | $396M | $527M | $659M | $602M | $435M | $360M | $379M | · | $319M | $237M | $224M | · | $202M | |
| Inventory | $904M | $1.00B | $915M | $1.08B | $994M | $941M | $750M | $566M | $486M | $374M | · | $244M | $227M | $203M | · | $221M | |
| Other Current Assets | $106M | $188M | $172M | $192M | $128M | $105M | $90M | $165M | $75M | $83M | · | $154M | $148M | $180M | · | $131M | |
| Current Assets | $2.22B | $2.31B | $2.54B | $2.72B | $2.66B | $2.43B | $3.07B | $2.69B | $2.68B | $2.46B | · | $2.45B | $2.47B | $2.49B | · | $2.63B | |
| PP&E (Net) | $326M | $336M | $345M | $359M | $372M | $361M | $340M | $306M | $276M | $249M | · | $212M | $189M | $183M | · | $181M | |
| PP&E (Gross) | · | · | $626M | · | · | · | $574M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $280M | · | · | · | $234M | · | · | · | · | · | · | · | · | · | |
| Intangibles | $31M | $31M | $29M | $30M | $31M | $26M | $27M | $28M | $28M | $29M | · | $20M | $18M | $7M | · | $13M | |
| Other Non-current Assets | $146M | $152M | $156M | $73M | $83M | $81M | $80M | $84M | $136M | $176M | · | $137M | $163M | $162M | · | $293M | |
| Total Assets | $3.19B | $3.18B | $3.35B | $3.49B | $3.68B | $3.47B | $3.96B | $3.60B | $3.42B | $3.22B | · | $3.11B | $3.13B | $3.06B | · | $3.16B | |
| Accounts Payable | $51M | $70M | $281M | $94M | $137M | $156M | $214M | $119M | $107M | $92M | · | $88M | $110M | $107M | · | $118M | |
| Accrued Liabilities | $325M | $302M | $360M | $296M | $377M | $392M | $374M | $345M | $350M | $283M | · | $322M | $327M | $346M | · | $369M | |
| Current Liabilities | $503M | $499M | $1.10B | $921M | $920M | $606M | $732M | $699M | $688M | $609M | · | $451M | $499M | $537M | · | $603M | |
| Capital Leases | $198M | $199M | $199M | $215M | $214M | $205M | $192M | $170M | $144M | $140M | · | $135M | $129M | $54M | · | $35M | |
| Other Non-current Liabilities | $2M | $2M | $2M | $1M | $1M | $927.0K | $2M | $1M | $7M | $8M | · | $0 | $38.0K | $38.0K | · | $0 | |
| Total Liabilities | $1.66B | $1.67B | $2.21B | $2.17B | $2.32B | $2.32B | $2.44B | $2.38B | $2.35B | $2.26B | · | $2.35B | $2.38B | $2.35B | · | $2.73B | |
| Long-term Debt | $848M | $838M | $829M | $1.04B | · | · | $1.14B | $1.23B | $1.23B | $1.24B | · | $1.24B | $1.24B | $1.23B | · | $1.54B | |
| Total Debt | · | · | · | · | · | · | · | $92M | $92M | $106M | · | · | · | · | · | · | |
| Common Stock | $11.0K | $11.0K | $11.0K | $11.0K | $10.0K | $10.0K | $10.0K | $10.0K | $10.0K | $9.0K | · | $9.0K | $9.0K | $9.0K | · | $9.0K | |
| Retained Earnings | $-4.55B | $-4.55B | $-4.88B | $-4.64B | $-4.46B | $-4.66B | $-4.21B | $-4.37B | $-4.40B | $-4.41B | · | $-4.49B | $-4.45B | $-4.43B | · | $-3.80B | |
| Treasury Stock | $25M | $25M | $25M | $25M | $25M | · | $0 | · | · | · | · | · | · | · | · | · | |
| AOCI | $-565.0K | $-121.0K | $272.0K | $220.0K | $-51.0K | $34.0K | $-218.0K | $2M | $-1M | $-691.0K | · | $-638.0K | $-1M | $-419.0K | · | $-3M | |
| Stockholders' Equity | $1.53B | $1.51B | $1.14B | $1.32B | $1.36B | $1.14B | $1.53B | $1.22B | $1.08B | $961M | $859M | $764M | $741M | $713M | $385M | $431M | |
| Liabilities + Equity | $3.19B | $3.18B | $3.35B | $3.49B | $3.68B | $3.47B | $3.96B | $3.60B | $3.42B | $3.22B | · | $3.11B | $3.13B | $3.06B | · | $3.16B | |
| Shares Outstanding | 105,623,500 | 105,571,146 | 104,964,220 | 104,768,111 | 97,706,074 | 98,254,898 | 96,900,496 | 95,493,005 | 95,282,600 | 94,490,157 | · | 93,537,355 | 93,273,541 | 93,140,135 | · | 87,766,199 |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $10M | $11M | $5M | $18M | $11M | $10M | $10M | $10M | $9M | $9M | $11M | $11M | $11M | $11M | $11M | $11M | |
| Stock-based Comp | $24M | $29M | $30M | $15M | $37M | $41M | $50M | $43M | $50M | $41M | $46M | $48M | $47M | $41M | $51M | $50M | |
| Amort. of Intangibles | $717.0K | $691.0K | $677.0K | $677.0K | $667.0K | $601.0K | $601.0K | $602.0K | $601.0K | $601.0K | $763.0K | $439.0K | $179.0K | $178.0K | $179.0K | $178.0K | |
| Restructuring | · | · | $1M | $41M | · | · | $0 | $0 | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | $-574M | · | · | · | $-187M | · | · | · | $-328M | · | · | · | $255M | · | · | |
| Operating Cash Flow | $197M | $-203M | $131M | $-15M | $261M | $-583M | $92M | $-71M | $15M | $-242M | $-55M | $-115M | $-122M | $-209M | $-92M | $-65M | |
| CapEx | $555.0K | $2M | $4M | $23M | $32M | $44M | $38M | $37M | $29M | $32M | $19M | $30M | $18M | $9M | $8M | $8M | |
| Investing Cash Flow | $-93M | $-134M | $96M | $232M | $32M | $-291M | $764M | $-129M | $-99M | $219M | $-64M | $-211M | $97M | $12M | $10M | $19M | |
| Stock Issued | · | · | $0 | · | · | · | $0 | · | · | · | · | · | · | · | · | · | |
| Stock Repurchased | · | · | $0 | $0 | · | · | $0 | $0 | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $0 | $241.0K | $-39M | $-118M | $-24M | $12M | $49M | $14M | $40M | $22M | $2M | $15M | $6M | $102M | $11M | $216M | |
| Net Change in Cash | $104M | $-337M | $188M | $100M | $270M | $-862M | $905M | $-186M | $-44M | $-1M | $-117M | $-310M | $-20M | $-95M | $-72M | $171M | |
| Taxes Paid | $8M | $2M | $16M | $1M | $19M | $835.0K | $11M | $4M | $7M | $909.0K | $6M | $4M | $5M | $535.0K | $339.0K | · | |
| Free Cash Flow | · | $-205M | · | · | · | $-627M | · | · | · | $-275M | · | · | · | $-219M | · | · | |
| Levered FCF | · | $-184M | · | · | · | $-622M | · | · | · | $-278M | · | · | · | $-225M | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 3.3% | 49.0% | · | -25.9% | 18.9% | -40.3% | · | 4.8% | -0.19% | 8.4% | · | -6.3% | -51.1% | -54.5% | · | -57.0% | |
| Net Margin | -1.2% | 45.3% | · | -45.1% | 32.2% | -60.1% | · | 7.2% | 1.8% | 8.7% | · | -12.3% | -9.2% | -203.8% | · | -111.9% | |
| Pretax Margin | -0.44% | 47.0% | · | -48.6% | 25.1% | -51.5% | · | 7.3% | 3.7% | 10.0% | · | -10.0% | -5.6% | -202.2% | · | -111.4% | |
| EBITDA Margin | 3.3% | 50.5% | · | -25.9% | 18.9% | -39.0% | · | 4.8% | -0.19% | 10.6% | · | -6.3% | -51.1% | -50.0% | · | -57.0% | |
| ROA | -0.14% | 10.0% | · | -5.1% | 5.5% | -13.4% | · | 1.0% | 0.20% | 1.1% | · | -1.3% | -0.78% | -16.9% | · | -8.9% | |
| ROE | -0.34% | 25.0% | · | -14.2% | 16.2% | -42.5% | · | 3.4% | 0.71% | 4.3% | · | -6.9% | -3.3% | -65.8% | · | -57.2% | |
| ROIC | 2.4% | 23.0% | · | -7.3% | 10.9% | -30.7% | · | 1.7% | -0.03% | 2.9% | · | -3.4% | -29.6% | -19.5% | · | -30.6% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.4 | 4.6 | · | 3.0 | 2.9 | 4.0 | · | 3.8 | 3.9 | 4.0 | · | 5.4 | 5.0 | 4.6 | · | 4.4 | |
| Quick Ratio | 2.3 | 2.1 | · | 1.4 | 1.4 | 2.0 | · | 2.3 | 2.6 | 2.9 | · | 4.6 | 4.2 | 3.9 | · | 3.8 | |
| Debt / Equity | · | · | · | · | · | · | · | 0.1 | 0.1 | 0.1 | · | · | · | · | · | · | |
| Interest Coverage | -0.6 | -16.5 | · | -13.7 | 22.1 | 66.7 | · | 4.5 | -0.1 | 8.4 | · | -4.0 | -25.6 | -21.8 | · | -8.9 |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.2 | · | 0.1 | 0.2 | 0.2 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 0.9 | 1.4 | · | 1.0 | 1.4 | 1.4 | · | 1.2 | 1.2 | 1.4 | · | 1.3 | 1.2 | 1.3 | · | 1.3 |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $14.46 | $14.26 | · | $12.60 | $13.89 | $11.63 | · | $12.79 | $11.30 | $10.17 | · | $8.17 | $7.95 | $7.65 | · | $4.91 | |
| Revenue / Share | $3.81 | $5.99 | · | $3.98 | $5.73 | $7.65 | · | $4.65 | $3.66 | $4.17 | · | $3.73 | $2.94 | $2.87 | · | $2627.80 | |
| Cash Flow / Share | · | $-1.66 | · | · | · | $-5.99 | · | · | · | $-2.44 | · | · | · | $-2.37 | · | · | |
| Cash / Share | $5.41 | $4.40 | · | $5.85 | $5.23 | $2.45 | · | $2.07 | $4.03 | $4.52 | · | $5.79 | $9.13 | $9.36 | · | $11.83 | |
| EPS (TTM) | $-1.60 | $0.34 | · | $-1.71 | $-0.87 | $-2.69 | · | $1.57 | $0.77 | $0.43 | · | $-7.83 | $-10.31 | $-12.69 | · | $-8.22 |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.97B | $2.18B | · | $2.41B | $2.48B | $2.23B | · | $1.64B | $1.50B | $1.40B | · | $1.10B | $1.00B | $976M | · | $876M | |
| Net Income TTM | $-137M | $65M | · | $-142M | $-58M | $-248M | · | $122M | $47M | $17M | · | $-691M | $-908M | $-1.12B | · | $-716M | |
| Market Cap | $1.90B | $2.30B | · | $2.02B | $1.67B | $6.27B | · | $11.93B | $15.05B | $12.23B | · | $11.34B | $10.68B | $12.84B | · | $9.70B | |
| Enterprise Value | · | · | · | · | · | · | · | $10.82B | $13.69B | $10.95B | · | · | · | · | · | · | |
| P/E | -11.2 | 64.0 | · | -11.3 | -19.7 | -23.7 | · | 79.5 | 205.2 | 301.1 | · | -15.5 | -11.1 | -10.9 | · | -13.4 | |
| P/S | 1.0 | 1.1 | · | 0.8 | 0.7 | 2.8 | · | 7.3 | 10.0 | 8.7 | · | 10.3 | 10.6 | 13.2 | · | 11.1 | |
| P/B | 1.2 | 1.5 | · | 1.5 | 1.2 | 5.5 | · | 9.8 | 14.0 | 12.7 | · | 14.8 | 14.4 | 18.0 | · | 22.5 | |
| P / Tangible Book | 1.3 | 1.6 | · | 1.6 | 1.3 | 5.6 | · | 10.0 | 14.4 | 13.1 | · | 15.2 | 14.8 | 18.2 | · | 23.2 | |
| P / Cash Flow | · | -11.3 | · | · | · | -10.7 | · | · | · | -50.5 | · | · | · | -61.3 | · | · | |
| EV / Revenue | · | · | · | · | · | · | · | 6.6 | 9.1 | 7.8 | · | · | · | · | · | · | |
| Earnings Yield | -8.9% | 1.6% | · | -8.9% | -5.1% | -4.2% | · | 1.3% | 0.49% | 0.33% | · | -6.5% | -9.0% | -9.2% | · | -7.4% |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $2.20B | $1.90B | $1.24B | $933M | $702M |
| Operating Margin % | -31.8% | 11.5% | -21.5% | -57.5% | -65.5% |
| Net Income | $-713M | $235M | $-536M | $-703M | $-419M |
| Diluted EPS | $-7.13 | $2.34 | $-5.80 | $-8.03 | $-5.15 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Debt / Equity | · | 0.0 | 0.1 | · | · |
| Current Ratio | 2.3 | 4.2 | 3.9 | 4.1 | 5.8 |
| Quick Ratio | 1.2 | 2.7 | 3.2 | 3.6 | 5.0 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | $-307M | $-343M | $-577M | $-356M | $-482M |
Institutional owners (13F) 366 filers · $2.3B total · As of Sept. 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 50 (-9 vs prior Q) | 60 (+14 vs prior Q) | 101 (-10 vs prior Q) | 125 (-17 vs prior Q) | +3.1M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| BlackRock, Inc. | $341,339,398 | 18,994,958 | 14.85% | Shares |
| VANGUARD GROUP INC | $254,166,887 | 11,810,729 | 11.06% | Shares |
| STATE STREET CORP | $160,222,137 | 8,916,090 | 6.97% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $150,543,136 | 8,377,470 | 6.55% | Shares |
| TWO SIGMA INVESTMENTS, LP | $82,639,268 | 4,598,735 | 3.60% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $82,513,837 | 4,591,755 | 3.59% | Shares |
| FIRST TRUST ADVISORS LP | $78,456,086 | 4,365,951 | 3.41% | Shares |
| AQR CAPITAL MANAGEMENT LLC | $76,867,492 | 4,325,689 | 3.35% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $49,818,796 | 2,771,758 | 2.17% | Shares |
| Erste Asset Management GmbH | $45,513,625 | 2,568,945 | 1.98% | Shares |
| TWO SIGMA ADVISERS, LP | $44,575,108 | 2,071,334 | 1.94% | Shares |
| MARSHALL WACE, LLP | $39,642,216 | 2,206,022 | 1.73% | Shares |
| MORGAN STANLEY | $39,581,468 | 2,202,641 | 1.72% | Shares |
| Aberdeen Group plc | $39,443,216 | 2,194,948 | 1.72% | Shares |
| BANK OF AMERICA CORP /DE/ | $36,946,051 | 2,055,985 | 1.61% | Shares |
| GOLDMAN SACHS GROUP INC | $36,703,734 | 2,042,501 | 1.60% | Shares |
| UBS Group AG | $29,190,737 | 1,624,415 | 1.27% | Shares |
| FEDERATED HERMES, INC. | $28,578,248 | 1,590,331 | 1.24% | Shares |
| LMR Partners LLP | $25,021,428 | 1,392,400 | 1.09% | Put option |
| CITADEL ADVISORS LLC | $23,727,588 | 1,320,400 | 1.03% | Call option |
| NORTHERN TRUST CORP | $21,756,855 | 1,210,732 | 0.95% | Shares |
| MILLENNIUM MANAGEMENT LLC | $21,446,620 | 1,193,468 | 0.93% | Shares |
| CITIGROUP INC | $20,755,457 | 1,155,006 | 0.90% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $20,151,163 | 1,121,378 | 0.88% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $17,616,368 | 980,321 | 0.77% | Shares |
| Connor, Clark & Lunn Investment Management Ltd. | $17,493,669 | 973,493 | 0.76% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $16,823,514 | 936,200 | 0.73% | Put option |
| Invesco Ltd. | $16,233,721 | 903,379 | 0.71% | Shares |
| Legal & General Group Plc | $15,770,961 | 877,627 | 0.69% | Shares |
| 683 Capital Management, LLC | $14,061,525 | 782,500 | 0.61% | Shares |
| Bank of New York Mellon Corp | $13,911,725 | 774,164 | 0.61% | Shares |
| ADAR1 Capital Management, LLC | $13,129,763 | 730,649 | 0.57% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $12,640,823 | 703,629 | 0.55% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $12,548,685 | 698,313 | 0.55% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $12,240,212 | 681,147 | 0.53% | Shares |
| Jump Financial, LLC | $12,209,627 | 679,445 | 0.53% | Shares |
| Voleon Capital Management LP | $12,116,183 | 674,245 | 0.53% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $12,059,667 | 671,100 | 0.52% | Call option |
| Qube Research & Technologies Ltd | $10,958,034 | 609,796 | 0.48% | Shares |
| MACKENZIE FINANCIAL CORP | $10,774,381 | 599,576 | 0.47% | Shares |
| HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC | $10,165,988 | 565,720 | 0.44% | Shares |
| JPMORGAN CHASE & CO | $9,345,699 | 544,392 | 0.41% | Shares |
| Point72 Asset Management, L.P. | $9,181,017 | 510,908 | 0.40% | Shares |
| PRINCIPAL FINANCIAL GROUP INC | $9,175,572 | 510,605 | 0.40% | Shares |
| Casdin Capital, LLC | $8,445,900 | 470,000 | 0.37% | Shares |
| Assenagon Asset Management S.A. | $8,165,119 | 454,375 | 0.36% | Shares |
| PANAGORA ASSET MANAGEMENT INC | $8,120,068 | 451,868 | 0.35% | Shares |
| Hudson Bay Capital Management LP | $8,086,500 | 450,000 | 0.35% | Shares |
| Man Group plc | $7,154,647 | 398,144 | 0.31% | Shares |
| PRUDENTIAL FINANCIAL INC | $7,083,235 | 394,170 | 0.31% | Shares |
Activists & 5%+ owners 6 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Richard J. Barry (2) | May 5, 2015 | · | Initial filing | · | SEC |
| George W. Haywood, Cheryl Haywood, Rockall Emerging Markets Master Fund Ltd., Meldrum Asset Management, LLC, Con Egan, Conor O’Driscoll ×2 filings | April 22, 2010 | · | Initial filing | · | SEC |
| Eastbourne Capital Management, L.L.C., Richard Jon Barry, Black Bear Offshore Master Fund, L.P., Black Bear Fund I, L.P., Black Bear Fund II, L.L.C. ×4 filings | March 8, 2010 | · | Initial filing | · | SEC |
| Medtronic, Inc., Medtronic International, Ltd. | Feb. 14, 2005 | · | Initial filing | Passive investment | SEC |
| Undisclosed reporting person | Jan. 8, 2002 | · | Initial filing | Passive investment | SEC |
| Undisclosed reporting person | June 29, 2001 | · | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 65 insiders · 29 officers · 18 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Michael Severino | Chief Executive Officer | July 28, 2026 A | 756,104 | 0 | 0 | $0 |
| Douglas S Ingram | Chief Executive Officer | Dec. 7, 2025 A | 929,391 | 0 | 0 | $0 |
| David J Boyle II | CEO | Aug. 27, 2010 P | 70,282 | 0 | 0 | $0 |
| Leslie Hudson | Former CEO | July 30, 2010 M | 384,559 | 0 | 0 | $0 |
| Denis R Burger | Chief Executive Officer | April 3, 2007 A | 151,717 | 0 | 0 | $0 |
| Ryan Ho-Yan Wong | Chief Financial Officer | Sept. 4, 2026 F | 121,792 | 0 | 0 | $0 |
| Sandesh Mahatme | EVP, CFO & CBO | July 8, 2020 M | 20,260 | 0 | 0 | $0 |
| Louise Rodino-Klapac | President, R&D and Tech Ops | Sept. 4, 2026 F | 203,900 | 0 | 0 | $0 |
| Ian Michael Estepan | Chief Operating Officer | Sept. 4, 2026 F | 177,184 | 0 | 1 | $-294,202 |
| Cristin Rothfuss | EVP, General Counsel | Sept. 4, 2026 F | 115,519 | 0 | 0 | $0 |
| Bilal Arif | Chief Tech Ops Officer | Aug. 5, 2025 A | 32,500 | 0 | 0 | $0 |
| Dallan Murray | Chief Customer Officer | March 10, 2025 A | 38,202 | 0 | 0 | $0 |
| Ryan Edward Brown | EVP, General Counsel | June 25, 2024 M | 17,129 | 0 | 0 | $0 |
| William Ciambrone | EVP | March 7, 2022 A | 22,099 | 0 | 0 | $0 |
| Joseph Bratica | Principal Financial Officer | Dec. 11, 2020 M | 8,140 | 0 | 0 | $0 |
| David T Howton | EVP, General Counsel | June 22, 2020 M | 31,871 | 0 | 0 | $0 |
| Alexander Cumbo | EVP, Chief Commercial Officer | Feb. 28, 2020 A | 8,567 | 0 | 0 | $0 |
| Shamim Ruff | SVP, Chief Regulatory Affairs | May 22, 2018 M | 31,936 | 0 | 0 | $0 |
| Guriqbal S. Basi | SVP, Chief Scientific Officer | March 5, 2018 A | · | 0 | 0 | $0 |
| Arthur M Krieg | SVP, Chief Scientific Officer | Jan. 13, 2014 A | · | 0 | 0 | $0 |
| Michael A Jacobsen | VP of Finance and PAO | Aug. 23, 2012 A | 7,500 | 0 | 0 | $0 |
| Bracha Ephrat Toshav | Sr VP & General Counsel | Aug. 31, 2011 A | · | 0 | 0 | $0 |
| Melinda G Mile | Controller and PAO | Aug. 31, 2011 A | · | 0 | 0 | $0 |
| Peter S Linsley | SVP & Chief Scientific Officer | May 16, 2011 A | · | 0 | 0 | $0 |
| Graham Johnson | Sr VP Preclinical Dev & Rsrch | Aug. 23, 2010 A | · | 0 | 0 | $0 |
| Paul Medeiros | SVP Business Development | Aug. 23, 2010 A | · | 0 | 0 | $0 |
| Stephen B Shrewsbury | SVP/Regulatory Affairs | Aug. 23, 2010 A | 60,000 | 0 | 0 | $0 |
| Patrick L Iversen | Sr VP of Research & Devlopment | Aug. 23, 2010 A | 86,303 | 0 | 0 | $0 |
| Dwight D Weller | Sr. VP Chemistry & Mfg. | Aug. 23, 2010 A | 314,741 | 0 | 0 | $0 |
| Michael Andrew Chambers | Director | June 4, 2026 A | 27,535 | 0 | 0 | $0 |
| Stephen Mayo | Director | June 4, 2026 A | 18,640 | 0 | 1 | $-123,208 |
| Kathryn Jean Boor | Director | June 4, 2026 A | 25,138 | 0 | 0 | $0 |
| Claude Nicaise | Director | June 4, 2026 A | 48,407 | 0 | 0 | $0 |
| Richard Barry | Director | June 4, 2026 A | 2,983,542 | 0 | 0 | $0 |
| Hans Lennart Rudolf Wigzell | Director | June 4, 2026 A | 42,098 | 0 | 0 | $0 |
| Deirdre P Connelly | Director | June 4, 2026 A | 22,100 | 0 | 0 | $0 |
| Kathleen M Behrens | Director | June 4, 2026 A | 214,357 | 0 | 0 | $0 |
| Mary Ann Gray | Director | March 7, 2022 A | 12,356 | 0 | 0 | $0 |
| John C Martin | Director | March 3, 2021 A | 7,913 | 0 | 0 | $0 |
| Michael W Bonney | Director | Feb. 28, 2020 A | 9,126 | 0 | 0 | $0 |
| Edward M. Kaye MD | Director | Aug. 3, 2017 M | 71,229 | 0 | 0 | $0 |
| Jean-Paul Kress | Director | March 10, 2017 A | 2,000 | 0 | 0 | $0 |
| Ben Gil Price | Director | March 14, 2016 P | 42,830 | 0 | 0 | $0 |
| William Alden Goolsbee | Director | Feb. 29, 2016 A | 8,166 | 0 | 0 | $0 |
| EASTBOURNE CAPITAL MANAGEMENT LLC/CA | 10% owner | March 4, 2010 S | 5,659,211 | 0 | 0 | $0 |
| MEDTRONIC INC | 10% owner | May 25, 2004 S | 0 | 0 | 0 | $0 |
| Gilmore Neil O'Neill | · | March 3, 2021 A | 28,546 | 0 | 0 | $0 |
| Catherine Stehman-Breen | · | April 3, 2017 A | · | 0 | 0 | $0 |
| Jayant Aphale | · | Sept. 19, 2016 M | 11,490 | 0 | 0 | $0 |
| Nishan Garabedian Christopher | · | Feb. 27, 2015 A | 29,552 | 0 | 0 | $0 |
| Anthony R Chase | · | Feb. 27, 2015 A | 67,194 | 0 | 0 | $0 |
| John Hodgman | · | Feb. 27, 2015 A | 6,333 | 0 | 0 | $0 |
| Anthony Martignetti | · | June 4, 2013 A | · | 0 | 0 | $0 |
| Ryszard Kole | · | Feb. 9, 2010 A | 1,862,926 | 0 | 0 | $0 |
| George Weaver Haywood | · | Aug. 25, 2009 P | 8,213,717 | 0 | 0 | $0 |
| Michael D Casey | · | May 19, 2009 A | 5,000 | 0 | 0 | $0 |
| FORREST K MICHAEL | · | May 19, 2009 A | 15,000 | 0 | 0 | $0 |
| Christopher S Henney | · | March 31, 2009 A | · | 0 | 0 | $0 |
| John W Fara PHD | · | May 20, 2008 A | · | 0 | 0 | $0 |
| Peter D Ohanley | · | Feb. 28, 2008 A | · | 0 | 0 | $0 |
| Mark Miles Webber | · | Feb. 28, 2008 A | · | 0 | 0 | $0 |
| Alan P Timmins | · | Feb. 2, 2008 J | · | 0 | 0 | $0 |
| James B Hicks | · | May 22, 2007 A | 6,000 | 0 | 0 | $0 |
| Jack L Bowman | · | May 22, 2007 A | 5,000 | 0 | 0 | $0 |
| Joseph B Horn | · | March 22, 2006 A | · | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 56 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| PBE · Invesco Exchange-Traded Fund Trust | 2.63% | 620,211 SH | Oct. 2, 2026 | Daily |
| IBRN · iShares Trust | 2.18% | 7,938 SH | Sept. 11, 2026 | Daily |
| BBP · ETFis Series Trust I | 1.34% | 88,646 NS | July 31, 2026 | N-PORT |
| PSCH · Invesco Exchange-Traded Fund Trust … | 1.02% | 100,590 SH | Oct. 2, 2026 | Daily |
| HAPS · Harbor ETF Trust | 0.81% | 92,720 NS | July 31, 2026 | N-PORT |
| XSHQ · Invesco Exchange-Traded Fund Trust … | 0.50% | 82,108 SH | Oct. 2, 2026 | Daily |
| LABU · Direxion Shares ETF Trust | 0.45% | 151,157 NS | July 31, 2026 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0.44% | 5,675 SH | Oct. 2, 2026 | Daily |
| IBB · iShares Trust | 0.15% | 772,730 SH | Sept. 11, 2026 | Daily |
| SMDX · Tidal Trust III | 0.15% | 13,054 NS | July 31, 2026 | N-PORT |
| VFVA · VANGUARD WELLINGTON FUND | 0.14% | 64,607 SH | Aug. 19, 2026 | Daily |
| VIOG · VANGUARD ADMIRAL FUNDS | 0.13% | 76,657 SH | Aug. 19, 2026 | Daily |
| ESSC · Strategy Shares | 0.13% | 3,094 NS | July 31, 2026 | N-PORT |
| PWS · Pacer Funds Trust | 0.13% | 2,065 NS | July 31, 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.12% | 7,460 SH | Oct. 2, 2026 | Daily |
| QVMS · Invesco Exchange-Traded Fund Trust … | 0.11% | 15,261 SH | Oct. 2, 2026 | Daily |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.11% | 84,228 SH | Aug. 19, 2026 | Daily |
| FYC · First Trust Exchange-Traded AlphaDE… | 0.11% | 95,830 NS | July 31, 2026 | N-PORT |
| RWJ · Invesco Exchange-Traded Fund Trust … | 0.10% | 113,747 SH | Oct. 2, 2026 | Daily |
| VIOO · VANGUARD ADMIRAL FUNDS | 0.10% | 369,221 SH | Aug. 19, 2026 | Daily |
| VIOV · VANGUARD ADMIRAL FUNDS | 0.08% | 87,370 SH | Aug. 19, 2026 | Daily |
| IWM · iShares Trust | 0.07% | 2,658,934 SH | Sept. 11, 2026 | Daily |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.06% | 598,819 SH | Aug. 19, 2026 | Daily |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0.06% | 27,534 NS | July 31, 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0.05% | 1,332,977 SH | Aug. 19, 2026 | Daily |
| RSSL · Global X Funds | 0.05% | 49,826 NS | July 31, 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0.03% | 299,980 SH | Aug. 19, 2026 | Daily |
| FAD · First Trust Exchange-Traded AlphaDE… | 0.02% | 8,682 NS | July 31, 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0.02% | 46,891 NS | July 31, 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0.02% | 1,210,549 SH | Aug. 19, 2026 | Daily |
| VB · VANGUARD INDEX FUNDS | 0.02% | 2,292,990 SH | Aug. 19, 2026 | Daily |
| WSML · iShares Trust | 0.02% | 6,093 SH | Sept. 11, 2026 | Daily |
| DXUV · Dimensional ETF Trust | 0.02% | 6,769 NS | July 31, 2026 | N-PORT |
| PRF · Invesco Exchange-Traded Fund Trust | 0.01% | 68,063 SH | Oct. 2, 2026 | Daily |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.01% | 7,772 SH | Aug. 19, 2026 | Daily |
| IWO · iShares Trust | 0.01% | 67,657 SH | Sept. 11, 2026 | Daily |
| TILT · FlexShares Trust | 0.01% | 13,904 NS | July 31, 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0.01% | 83,934 NS | July 31, 2026 | N-PORT |
| DFSU · Dimensional ETF Trust | 0.01% | 11,994 NS | July 31, 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.00% | 8,729 NS | July 31, 2026 | N-PORT |
| ITOT · iShares Trust | 0.00% | 141,450 SH | Sept. 11, 2026 | Daily |
| DFUS · Dimensional ETF Trust | 0.00% | 37,436 NS | July 31, 2026 | N-PORT |
| IWV · iShares Trust | 0.00% | 25,570 SH | Sept. 11, 2026 | Daily |
| DFAU · Dimensional ETF Trust | 0.00% | 22,144 NS | July 31, 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.00% | 65,871 NS | July 31, 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 3,187,072 SH | Aug. 19, 2026 | Daily |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.00% | 80,332 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 8,458 SH | Aug. 19, 2026 | Daily |
| ESGV · VANGUARD WORLD FUND | 0.00% | 23,052 SH | Aug. 19, 2026 | Daily |
| IJR · iShares Trust | · | 6,444,975 SH | Sept. 10, 2026 | Daily |
| IJT · iShares Trust | · | 613,122 SH | Sept. 9, 2026 | Daily |
| IJS · iShares Trust | · | 369,121 SH | Sept. 8, 2026 | Daily |
| IWN · iShares Trust | · | 910,181 SH | Sept. 11, 2026 | Daily |
| XJR · iShares Trust | · | 14,552 SH | Aug. 31, 2026 | Daily |
| ISCB · iShares Trust | · | 4,621 SH | Sept. 11, 2026 | Daily |
| ISCV · iShares Trust | · | 22,361 SH | Sept. 11, 2026 | Daily |
SRPT Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
12-Month Price Target
22 analysts · 2026-10-03Mean target $21.73 +24.2%
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| SRPT | $2.26B | -3.0 | 15.6% | -32.5% | -57.1% | · |
| BHVN | $1.50B | -1.6 | · | · | -310.8% | · |
| PVLA | $1.30B | -28.2 | 65.3% | -1610.6% | -110.1% | · |
| ABSI | $529M | -4.2 | -38.2% | -4113.7% | -63.5% | · |
| AGIO | $1.59B | -3.8 | 48.0% | -764.0% | -32.2% | · |
| VIR | $841M | -1.9 | -7.6% | -638.9% | -51.1% | · |
| GENB | · | · | · | · | · | · |
| NVAX | $1.09B | 2.6 | 64.7% | 39.2% | -977.1% | · |
| NTLA | $1.05B | -2.4 | 16.9% | -609.8% | -59.5% | · |
| STOK | $1.87B | -264.5 | 404.5% | -3.7% | -2.0% | · |
Latest News Recent headlines mentioning this company
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.